PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
出版年份 2019 全文链接
标题
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume -, Issue -, Pages 201822001
出版商
Proceedings of the National Academy of Sciences
发表日期
2019-04-27
DOI
10.1073/pnas.1822001116
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
- (2019) James B. Wing et al. IMMUNITY
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy
- (2018) Mathieu F. Chevalier et al. EUROPEAN UROLOGY
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells
- (2018) Chaido Stathopoulou et al. IMMUNITY
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
- (2018) Danbee Ha et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori
- (2016) Hirotsugu Nagase et al. INTERNATIONAL JOURNAL OF CANCER
- Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
- (2016) Takuro Saito et al. NATURE MEDICINE
- Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
- (2016) Baihao Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+T Cells
- (2015) Hyo Jin Park et al. JOURNAL OF IMMUNOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3highregulatory T cells in humans
- (2015) Makoto Miyara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
- (2014) J. Christoph Vahl et al. IMMUNITY
- Continuous requirement for the TCR in regulatory T cell function
- (2014) Andrew G Levine et al. NATURE IMMUNOLOGY
- FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS
- (2014) Yawei Liu et al. NATURE MEDICINE
- An obligate cell-intrinsic function for CD28 in Tregs
- (2013) Ruan Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
- (2008) Y. Onishi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started